⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

DRREDDY - IntraDay Trade Analysis with Live Signals

← Back to List

⭐ Rating: 2.5

Last Updated Time : 19 Sept 26, 09:42 am

Key Parameters

⭐ IntraDay Trade Rating: 2.5

RSI55.1
MACD-7.12
Volume31,30,379
Avg Vol 1Wk21,66,046
Low price1,080 ₹
High price1,415 ₹
Current Price1,171 ₹
DMA 501,188 ₹
Show all parameters (20 more)
Stock CodeDRREDDY
Market Cap97,995 Cr.
High / Low1,415 ₹
Stock P/E148
Book Value376 ₹
Dividend Yield0.69 %
ROCE12.1 %
ROE10.2 %
Face Value1.00 ₹
DMA 2001,236 ₹
Chg in FII Hold-0.47 %
Chg in DII Hold1.03 %
PAT Qtr405 Cr.
PAT Prev Qtr-219 Cr.
PEG Ratio28.2
Debt to equity0.18
52w Index27.2 %
Qtr Profit Var-86.3 %
EPS7.95 ₹
Industry PE34.8

🧾 Trade Setup

I recommend a buy at 1,185 ₹ with an initial stop-loss order placed at 1,160 ₹, targeting a profit of 25₹ – 30₹. A secondary exit level should be set at 1,210 ₹ to secure gains if the stock breaks through this resistance level. Overall, while the volume is strong and the news is positive, the extreme valuation demands careful risk management, making this a moderately risky intraday trade.

✅ Positive

Immediate volume is very strong at 31.3M, significantly above the one-week average of 21.7M. The recent news regarding the Dengue shot deal provides a potential catalyst for continued buying interest today.

⚠️ Limitation

The extremely high P/E ratio of 148 relative to the industry’s PE of 34.8 indicates significant overvaluation, which presents a substantial risk if momentum stalls. Furthermore, the negative profit growth from the previous quarter (PAT Qtr: -219 Cr.) raises concerns about short-term sustainability and could trigger a sharp correction should the stock fail to maintain its upward trajectory.

🏭 Industry

The pharmaceutical sector is currently experiencing moderate volatility driven by regulatory changes and vaccine development opportunities, particularly in emerging markets. The Upstox report highlights potential upside for Dr. Reddy’s due to the exclusive agreement regarding the Dengue shot distribution, which could bolster investor confidence.

Choose Technical Analysis or Fundamental Analysis above to load it.

How DRREDDY Rates Across All Strategies

★ 2.8
Entry Price: 1,165 ₹ – Triggering a long position now represents an o…
Intraday
★ 2.5
You're viewing this analysis below.
★ 2.5
An entry price zone between 1,080 ₹ and 1,120 ₹ would represent a rea…
★ 2.8
Short-term entry could be considered around 1,165 ₹ – 1,180 ₹, utiliz…
★ 2.3
We recommend a cautious entry zone around 1,080 ₹, representing a nea…

NIFTY 50 · Intraday Trading

NEXT 50 · Intraday Trading

MIDCAP · Intraday Trading

SMALLCAP · Intraday Trading